TransCode Advances TTX-MC138 to Phase 2 Trials for ctDNA-Positive Cancers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: PRnewswire
- Clinical Trial Success: TransCode Therapeutics has successfully met the primary safety endpoint in its Phase 1a dose escalation trial, with no dose-limiting toxicities reported among patients, indicating the safety and potential efficacy of its therapeutic candidate TTX-MC138.
- Significant Disease Stabilization: TTX-MC138, an investigational inhibitor targeting the key metastatic driver microRNA-10b, has demonstrated durable disease control in multiple patients, further validating its application potential in treating high-risk cancers.
- Phase 2 Development Plan: Following the positive results from Phase 1a, TransCode is advancing TTX-MC138 into Phase 2a clinical development to evaluate its efficacy in patients with circulating tumor DNA (ctDNA) positive colorectal cancer post-curative intent therapy, aiming to provide new treatment options for this high-risk patient population.
- Innovative Treatment Outlook: The development of TTX-MC138 not only offers new hope for metastatic cancer patients but also has the potential to advance RNA therapeutic strategies through precision treatment targeting ctDNA, enhancing the company's competitive position in the oncology immunotherapy market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RNAZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RNAZ
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
TransCode to Host Live Webcast on TTX-MC138 Phase 2a Trial and Pipeline
- Clinical Trial Launch: TransCode Therapeutics has announced the initiation of its lead antagomiR program TTX-MC138 in a Phase 2a clinical trial targeting ctDNA-positive colorectal cancer, marking a significant advancement in the oncology sector and likely attracting increased investor interest.
- Webcast Announcement: The company will host its first live virtual R&D webcast on June 18, 2026, at 10:00 a.m. ET, providing strategic, scientific, and clinical updates about its development pipeline, aimed at bolstering investor confidence in the company's future prospects.
- Investment Thesis Articulation: CEO Philippe P Calais emphasized that the enrollment of TTX-MC138 represents a meaningful inflection point on a capital-disciplined timeline, which is expected to create new growth opportunities and attract further capital investment.
- Multi-Platform Pipeline: TransCode's three-platform pipeline includes not only TTX-MC138 but also other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells, further solidifying its market position in cancer treatment.
See More
Biotech Stocks Pre-Market Trading Insights
- Significant Pre-Market Gains: Picard Medical, Inc. (PMI) surged 34% to $0.36 in pre-market trading, indicating strong investor interest likely driven by positive clinical trial updates, which may attract further investment.
- Other Gaining Stocks: Connect Biopharma Holdings Limited (CNTB) rose 14% to $2.44, while LifeVantage Corporation (LFVN) increased 10% to $9.46, suggesting an improving investor sentiment in the biotech sector that could enhance overall industry performance.
- Pre-Market Decliners: TransCode Therapeutics, Inc. (RNAZ) fell 22% to $4.13, reflecting negative market reactions to recent news, which may lead investors to reassess its future prospects.
- Market Sentiment Impact: The overall pre-market trading indicates volatility in biotech stocks, prompting investors to closely monitor clinical trial results and corporate developments to make more informed investment decisions.
See More
TransCode Advances TTX-MC138 to Phase 2 Trials for ctDNA-Positive Cancers
- Clinical Trial Success: TransCode Therapeutics has successfully met the primary safety endpoint in its Phase 1a dose escalation trial, with no dose-limiting toxicities reported among patients, indicating the safety and potential efficacy of its therapeutic candidate TTX-MC138.
- Significant Disease Stabilization: TTX-MC138, an investigational inhibitor targeting the key metastatic driver microRNA-10b, has demonstrated durable disease control in multiple patients, further validating its application potential in treating high-risk cancers.
- Phase 2 Development Plan: Following the positive results from Phase 1a, TransCode is advancing TTX-MC138 into Phase 2a clinical development to evaluate its efficacy in patients with circulating tumor DNA (ctDNA) positive colorectal cancer post-curative intent therapy, aiming to provide new treatment options for this high-risk patient population.
- Innovative Treatment Outlook: The development of TTX-MC138 not only offers new hope for metastatic cancer patients but also has the potential to advance RNA therapeutic strategies through precision treatment targeting ctDNA, enhancing the company's competitive position in the oncology immunotherapy market.
See More
TransCode Initiates Phase 2a Clinical Trial for TTX-MC138
- Clinical Trial Launch: TransCode Therapeutics has announced the initiation of its Phase 2a clinical trial for TTX-MC138, aimed at evaluating the drug's efficacy in colorectal cancer patients post-curative treatment, with an expected enrollment of up to 45 patients, showcasing the company's ongoing innovation in cancer treatment.
- Collaborative Platform Advantage: The trial is conducted in collaboration with Quantum Leap Healthcare Collaborative, leveraging its PRE-I-SPY clinical trial platform, integrating expertise from multiple National Cancer Centers to enhance treatment outcomes for minimal residual disease (MRD), further solidifying TransCode's position in the field of tumor immunotherapy.
- Importance of ctDNA Testing: The trial will focus on the role of ctDNA testing in reducing cancer recurrence risk, reflecting the increasing significance of this technology in colorectal cancer treatment, potentially offering patients more precise therapeutic options and improving long-term survival rates.
- Drug Safety and Efficacy: TTX-MC138 has achieved its primary safety endpoint in Phase 1 clinical trials, demonstrating promising anti-tumor effects, which lays the groundwork for more rigorous efficacy evaluations, potentially providing new treatment options for high-risk patients and driving future growth for the company.
See More
TransCode Appoints New Chair of Scientific Advisory Board
- New Chair Appointment: TransCode Therapeutics has appointed Dr. Anna Moore as Chair of its Scientific Advisory Board, a globally recognized expert in molecular imaging and RNA-targeted cancer therapeutics, expected to provide strategic guidance that will enhance the company's R&D efforts and drive innovative therapies forward.
- Research Agreement Signed: The company has executed a sponsored research agreement with Michigan State University aimed at accelerating the clinical development of its pipeline candidates, particularly focusing on its lead therapeutic candidate TTX-MC138, which is anticipated to bolster its competitive position in the market.
- Therapeutic Synergy Research: The research will evaluate the combination of TTX-MC138 with Seviprotimut-L to explore potential synergies, a strategy that could enhance therapeutic efficacy and address significant unmet medical needs in oncology.
- Industry Impact: Dr. Moore's addition not only strengthens the scientific leadership of the company but may also attract greater investor interest in TransCode's future growth potential, particularly in the innovative advancements in high-risk and advanced cancer treatments.
See More
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
TransCode to Host Live Webcast on TTX-MC138 Phase 2a Trial and Pipeline
- Clinical Trial Launch: TransCode Therapeutics has announced the initiation of its lead antagomiR program TTX-MC138 in a Phase 2a clinical trial targeting ctDNA-positive colorectal cancer, marking a significant advancement in the oncology sector and likely attracting increased investor interest.
- Webcast Announcement: The company will host its first live virtual R&D webcast on June 18, 2026, at 10:00 a.m. ET, providing strategic, scientific, and clinical updates about its development pipeline, aimed at bolstering investor confidence in the company's future prospects.
- Investment Thesis Articulation: CEO Philippe P Calais emphasized that the enrollment of TTX-MC138 represents a meaningful inflection point on a capital-disciplined timeline, which is expected to create new growth opportunities and attract further capital investment.
- Multi-Platform Pipeline: TransCode's three-platform pipeline includes not only TTX-MC138 but also other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells, further solidifying its market position in cancer treatment.
See More
Biotech Stocks Pre-Market Trading Insights
- Significant Pre-Market Gains: Picard Medical, Inc. (PMI) surged 34% to $0.36 in pre-market trading, indicating strong investor interest likely driven by positive clinical trial updates, which may attract further investment.
- Other Gaining Stocks: Connect Biopharma Holdings Limited (CNTB) rose 14% to $2.44, while LifeVantage Corporation (LFVN) increased 10% to $9.46, suggesting an improving investor sentiment in the biotech sector that could enhance overall industry performance.
- Pre-Market Decliners: TransCode Therapeutics, Inc. (RNAZ) fell 22% to $4.13, reflecting negative market reactions to recent news, which may lead investors to reassess its future prospects.
- Market Sentiment Impact: The overall pre-market trading indicates volatility in biotech stocks, prompting investors to closely monitor clinical trial results and corporate developments to make more informed investment decisions.
See More
TransCode Advances TTX-MC138 to Phase 2 Trials for ctDNA-Positive Cancers
- Clinical Trial Success: TransCode Therapeutics has successfully met the primary safety endpoint in its Phase 1a dose escalation trial, with no dose-limiting toxicities reported among patients, indicating the safety and potential efficacy of its therapeutic candidate TTX-MC138.
- Significant Disease Stabilization: TTX-MC138, an investigational inhibitor targeting the key metastatic driver microRNA-10b, has demonstrated durable disease control in multiple patients, further validating its application potential in treating high-risk cancers.
- Phase 2 Development Plan: Following the positive results from Phase 1a, TransCode is advancing TTX-MC138 into Phase 2a clinical development to evaluate its efficacy in patients with circulating tumor DNA (ctDNA) positive colorectal cancer post-curative intent therapy, aiming to provide new treatment options for this high-risk patient population.
- Innovative Treatment Outlook: The development of TTX-MC138 not only offers new hope for metastatic cancer patients but also has the potential to advance RNA therapeutic strategies through precision treatment targeting ctDNA, enhancing the company's competitive position in the oncology immunotherapy market.
See More
TransCode Initiates Phase 2a Clinical Trial for TTX-MC138
- Clinical Trial Launch: TransCode Therapeutics has announced the initiation of its Phase 2a clinical trial for TTX-MC138, aimed at evaluating the drug's efficacy in colorectal cancer patients post-curative treatment, with an expected enrollment of up to 45 patients, showcasing the company's ongoing innovation in cancer treatment.
- Collaborative Platform Advantage: The trial is conducted in collaboration with Quantum Leap Healthcare Collaborative, leveraging its PRE-I-SPY clinical trial platform, integrating expertise from multiple National Cancer Centers to enhance treatment outcomes for minimal residual disease (MRD), further solidifying TransCode's position in the field of tumor immunotherapy.
- Importance of ctDNA Testing: The trial will focus on the role of ctDNA testing in reducing cancer recurrence risk, reflecting the increasing significance of this technology in colorectal cancer treatment, potentially offering patients more precise therapeutic options and improving long-term survival rates.
- Drug Safety and Efficacy: TTX-MC138 has achieved its primary safety endpoint in Phase 1 clinical trials, demonstrating promising anti-tumor effects, which lays the groundwork for more rigorous efficacy evaluations, potentially providing new treatment options for high-risk patients and driving future growth for the company.
See More
TransCode Appoints New Chair of Scientific Advisory Board
- New Chair Appointment: TransCode Therapeutics has appointed Dr. Anna Moore as Chair of its Scientific Advisory Board, a globally recognized expert in molecular imaging and RNA-targeted cancer therapeutics, expected to provide strategic guidance that will enhance the company's R&D efforts and drive innovative therapies forward.
- Research Agreement Signed: The company has executed a sponsored research agreement with Michigan State University aimed at accelerating the clinical development of its pipeline candidates, particularly focusing on its lead therapeutic candidate TTX-MC138, which is anticipated to bolster its competitive position in the market.
- Therapeutic Synergy Research: The research will evaluate the combination of TTX-MC138 with Seviprotimut-L to explore potential synergies, a strategy that could enhance therapeutic efficacy and address significant unmet medical needs in oncology.
- Industry Impact: Dr. Moore's addition not only strengthens the scientific leadership of the company but may also attract greater investor interest in TransCode's future growth potential, particularly in the innovative advancements in high-risk and advanced cancer treatments.
See More
